Can Venlafaxine Cause Auditory Hallucinations?
Yes, venlafaxine can cause auditory hallucinations, though this is a rare adverse effect that typically occurs in specific clinical contexts, particularly when drug interactions elevate venlafaxine plasma concentrations or during withdrawal.
Evidence for Hallucinations with Venlafaxine
Direct Case Reports of Hallucinations
- Visual hallucinations and psychomotor agitation were documented in an 85-year-old woman taking venlafaxine 150 mg/day when combined with propafenone, a CYP2D6 inhibitor that likely increased venlafaxine plasma concentrations 1.
- The hallucinations resolved completely within 4 days of discontinuing venlafaxine 1.
- Hallucinations during withdrawal were reported in a patient undergoing slow tapering of venlafaxine, indicating that discontinuation can also precipitate hallucinatory experiences 2.
Mechanism and Risk Factors
The hallucinations appear related to:
- Drug-drug interactions that inhibit CYP2D6 (the primary metabolic pathway for venlafaxine), leading to elevated plasma concentrations 1.
- P-glycoprotein inhibition, which can further increase venlafaxine levels 1.
- Abrupt discontinuation or rapid tapering, which produces a withdrawal syndrome that may include hallucinations 2.
Special Considerations for Your Patient Context
Seizure History
Your patient's history of seizures is particularly relevant:
- Venlafaxine has been documented to cause seizures even at therapeutic doses (75 mg/day), with complex partial seizures reported 3.
- A generalized seizure occurred after venlafaxine overdose 4.
- Drug interactions with antituberculosis medications (isoniazid, levofloxacin) can lower seizure threshold when combined with venlafaxine 3.
Neuropathic Pain Treatment
While venlafaxine is recommended for neuropathic pain treatment:
- It is listed as a second-line agent (Level II, C evidence) for chemotherapy-induced peripheral neuropathy 5.
- Duloxetine has stronger evidence (Level I, B) and should be considered first-line 5.
- Venlafaxine has documented efficacy for neuropathic pain at doses of 150-225 mg/day 6, 7.
Clinical Monitoring Algorithm
If venlafaxine is prescribed despite these concerns:
- Screen for drug interactions that inhibit CYP2D6 or P-glycoprotein (propafenone, quinidine, fluoxetine, paroxetine) 1.
- Start at the lowest dose (37.5 mg/day) and titrate slowly, particularly given seizure history 3, 8.
- Monitor cardiovascular parameters weekly for 2-4 weeks (blood pressure, heart rate) 7.
- Watch for neuropsychiatric symptoms including hallucinations, agitation, and behavioral changes 1, 2.
- Never abruptly discontinue—always use slow tapering to avoid withdrawal-induced hallucinations 2, 7.
Common Pitfalls
- Combining with CYP2D6 inhibitors without dose adjustment can precipitate hallucinations 1.
- Rapid dose escalation in patients with seizure history increases risk of both seizures and psychiatric adverse effects 3.
- Abrupt discontinuation can cause a severe withdrawal syndrome including hallucinations, headache, nausea, and dysphoria 2.
- Ignoring cardiovascular monitoring at doses ≥225 mg/day, which are associated with cardiac conduction abnormalities 7.
Alternative Recommendation
Given your patient's seizure history and the documented risk of both seizures and hallucinations with venlafaxine, duloxetine would be a safer first-line choice for neuropathic pain 5, with pregabalin or gabapentin as alternatives if an SNRI is contraindicated 5.